TriangleMemantine Hydrochloride (NCT06789757)
Memantine Hydrochloride trial for Hepatocellular Carcinoma (NCT06789757). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, untreated, locally advanced hepatocellular carcinoma that cannot be removed surgically. Child-Pugh A5 or A6 liver function is required; selected remote, treated liver cancers are allowed.
The idea: add memantine, which blocks NMDA receptors, to atezolizumab and bevacizumab. Atezolizumab blocks PD-L1; bevacizumab blocks VEGF signaling. Researchers test whether this combination changes tumor response. Treatment uses 21-day cycles over six months, with memantine increases as tolerated.
This phase 2 study plans 19 patients. Arthur Winer leads at Inova’s two recruiting sites in Fairfax and Falls Church.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.